aTyr Pharma [LIFE] vs Vertex [VRTX] Detailed Stock Comparison
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: aTyr Pharma Inc wins in 7 metrics, Vertex Pharmaceuticals Inc. wins in 12 metrics, with 0 ties. Vertex Pharmaceuticals Inc. appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | aTyr Pharma Inc | Vertex Pharmaceuticals Inc. | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 14.35 | 28.40 | aTyr Pharma Inc |
| Price-to-Book Ratio | -42.41 | 5.92 | Vertex Pharmaceuticals Inc. |
| Debt-to-Equity Ratio | 0.62 | 10.91 | aTyr Pharma Inc |
| PEG Ratio | 8.46 | 0.88 | Vertex Pharmaceuticals Inc. |
| EV/EBITDA | 16.72 | 21.78 | aTyr Pharma Inc |
| Profit Margin (TTM) | 18.36% | 32.94% | Vertex Pharmaceuticals Inc. |
| Operating Margin (TTM) | 22.23% | 39.60% | Vertex Pharmaceuticals Inc. |
| EBITDA Margin (TTM) | 22.23% | 39.60% | Vertex Pharmaceuticals Inc. |
| Return on Equity | 21.03% | 22.54% | Vertex Pharmaceuticals Inc. |
| Return on Assets (TTM) | 10.00% | 12.16% | Vertex Pharmaceuticals Inc. |
| Free Cash Flow (TTM) | $29.95M | $3.19B | Vertex Pharmaceuticals Inc. |
| 1-Year Return | 200.19% | -2.31% | aTyr Pharma Inc |
| Price-to-Sales Ratio (TTM) | 2.65 | 9.22 | aTyr Pharma Inc |
| Enterprise Value | $1.31B | $105.96B | Vertex Pharmaceuticals Inc. |
| EV/Revenue Ratio | 3.38 | 8.83 | aTyr Pharma Inc |
| Gross Profit Margin (TTM) | 98.13% | 85.39% | aTyr Pharma Inc |
| Revenue per Share (TTM) | $24 | $47 | Vertex Pharmaceuticals Inc. |
| Earnings per Share (Diluted) | $1.14 | $15.32 | Vertex Pharmaceuticals Inc. |
| Beta (Stock Volatility) | N/A | 0.37 | N/A |
| Short % of Float | 9.90% | 1.78% | Vertex Pharmaceuticals Inc. |
aTyr Pharma Inc vs Vertex Pharmaceuticals Inc. Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| aTyr Pharma Inc | 5.41% | -1.44% | -24.23% | 37.77% | 2,153.42% | 2,064.47% |
| Vertex Pharmaceuticals Inc. | 1.24% | 1.69% | 3.09% | -3.36% | -1.15% | -0.37% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| aTyr Pharma Inc | 200.19% | 537.14% | 246.89% | 457.50% | -69.84% | -64.02% |
| Vertex Pharmaceuticals Inc. | -2.31% | 27.89% | 136.85% | 413.01% | 888.51% | 1,245.83% |
Performance & Financial Health Analysis: aTyr Pharma Inc vs Vertex Pharmaceuticals Inc.
| Metric | LIFE | VRTX |
|---|---|---|
| Market Information | ||
| Market Cap | $1.03B | $109.45B |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 497,145 | 1,057,061 |
| 90 Day Avg. Volume | 537,565 | 1,272,097 |
| Last Close | $16.45 | $450.46 |
| 52 Week Range | $0.64 - $32.50 | $362.50 - $507.92 |
| % from 52W High | -49.37% | -11.31% |
| All-Time High | $396.06 (Jun 01, 2015) | $519.88 (Nov 04, 2024) |
| % from All-Time High | -95.85% | -13.35% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.66% | 0.10% |
| Quarterly Earnings Growth | 1.57% | 0.31% |
| Financial Health | ||
| Profit Margin (TTM) | 0.18% | 0.33% |
| Operating Margin (TTM) | 0.22% | 0.40% |
| Return on Equity (TTM) | 0.21% | 0.23% |
| Debt to Equity (MRQ) | 0.62 | 10.91 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $-1.45 | $73.49 |
| Cash per Share (MRQ) | $2.00 | $26.01 |
| Operating Cash Flow (TTM) | $36.23M | $3.63B |
| Levered Free Cash Flow (TTM) | $51.01M | $2.57B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: aTyr Pharma Inc vs Vertex Pharmaceuticals Inc.
| Metric | LIFE (Apr 24, 2026) | VRTX (Apr 26, 2026) |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 14.35 | 28.40 |
| Forward P/E | 8.46 | 19.95 |
| PEG Ratio | 8.46 | 0.88 |
| Price to Sales (TTM) | 2.65 | 9.22 |
| Price to Book (MRQ) | -42.41 | 5.92 |
| Market Capitalization | ||
| Market Capitalization | $1.03B | $109.45B |
| Enterprise Value | $1.31B | $105.96B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 3.38 | 8.83 |
| Enterprise to EBITDA | 16.72 | 21.78 |
| Risk & Other Metrics | ||
| Beta | N/A | 0.37 |
| Book Value per Share (MRQ) | $-1.45 | $73.49 |
Financial Statements Comparison: aTyr Pharma Inc vs Vertex Pharmaceuticals Inc.
Financial Metrics
Loading Financial Charts...
Revenue
Operating Margin
Profit Margin
Long Term Debt
Income Flow Analysis
Financial Statements Comparison
Income Statement
| Metric | LIFE (2025) | VRTX (2025) |
|---|---|---|
| Revenue/Sales | 387.61M | 12.00B |
| Cost of Goods Sold | 6.73M | 1.65B |
| COGS % of Revenue | 1.7% | 13.8% |
| Gross Profit | 380.88M | 10.35B |
| Gross Margin | 98.3% | 86.2% |
| Research & Development | N/A | 4.04B |
| Operating Income (EBIT) | 72.92M | 4.55B |
| Operating Margin | 18.8% | 37.9% |
| EBITDA | 85.18M | 5.25B |
| EBITDA Margin | 22.0% | 43.7% |
| Pre-Tax Income | 75.74M | 4.64B |
| Pre-Tax Income % of Revenue | 19.5% | 38.7% |
| Income Tax | 4.59M | 690.00M |
| Income Tax % of Revenue | 1.2% | 5.7% |
| Net Income (Profit) | 71.15M | 3.95B |
| Profit Margin | 18.4% | 32.9% |
Balance Sheet & Liquidity Metrics
| Metric | LIFE (2025) | VRTX (2025) |
|---|---|---|
| Cash & Equivalents | 91.09M | 5.08B |
| Total Current Assets | 245.80M | 11.20B |
| Total Current Assets % of Revenue | 63.4% | 93.3% |
| Total Current Liabilities | 113.19M | 3.86B |
| Total Current Liabilities % of Revenue | 29.2% | 32.2% |
| Long-Term Debt | 1.23M | 1.95B |
| Long-Term Debt % of Revenue | 0.3% | 16.3% |
| Total Shareholders Equity | -24.12M | 18.67B |
| Retained Earnings | -102.51M | 13.56B |
| Retained Earnings % of Revenue | -26.4% | 113.0% |
| Property, Plant & Equipment | 2.32M | 1.56B |
Cash Flow Statement Comparison
| Metric | LIFE (2025) | VRTX (2025) |
|---|---|---|
| Operating Cash Flow | 38.96M | 3.77B |
| Operating Cash Flow % of Revenue | 10.1% | 31.4% |
| Capital Expenditures | -1.49M | -437.60M |
| Free Cash Flow | 29.95M | 3.19B |
| FCF Margin | 7.7% | 26.6% |
| Debt Repayment | N/A | -5.40M |
| Common Stock Repurchase | N/A | -2.39B |
Short Interest & Institutional Ownership Analysis
| Metric | LIFE | VRTX |
|---|---|---|
| Shares Short | 2.26M | 4.02M |
| Short Ratio | 4.29 | 2.80 |
| Short % of Float | 9.90% | 1.78% |
| Shares Outstanding | 62.56M | 253.99M |
| Float Shares | 25.92M | 253.24M |
| % Held by Insiders | 6.31% | 0.21% |
| % Held by Institutions | 23.87% | 97.60% |
| % Held by Public | 69.82% | 2.19% |
Dividend Analysis & Yield Comparison: aTyr Pharma Inc vs Vertex Pharmaceuticals Inc.
| Metric | LIFE | VRTX |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |